Live biotherapeutic products (LBPs) are defined by the U.S. FDA as biological products that contain live organisms applicable to the prevention, treatment, or cure of a disease or condition (1). LBP therapies continue to attract […]
Novome Biotechnologies, Inc., a clinical-stage biotechnology company developing engineered cellular therapies for the gut, announced positive results from a Phase 1 study of orally-administered NOV-001 in healthy volunteers. The Phase 1 study demonstrated the ability […]
The skin microbiome plays a fundamental role in human health, protecting against pathogens and antigens, while bolstering cutaneous immunity. Imbalances in the skin microbiome (i.e. “dysbiosis”) are highly associated with severity of skin disease, […]
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced positive topline results […]
SER-109 has the potential to be the first-ever live biotherapeutic product (LBP) to be produced commercially; the collaboration with Seres Therapeutics is a critical milestone for Bacthera, a joint venture between a Lonza Group Affiliate […]
ADM (NYSE: ADM), a global leader in nutrition and agricultural origination and processing, announced a significant expansion of its broad portfolio of health and wellness products and solutions with an agreement to purchase U.S.-based Deerland […]
For a long time, consumers have associated metabolic health with a healthy weight, but it goes far beyond that. Metabolic health is not about looking good, it is about being healthy, and it involves having […]
A new study has added numerous previously uncharacterized viral genomes and genes to the ever-increasing worldwide pool of human gut viromes. The study, published in mSystems, an open-access journal of the American Society for Microbiology, […]
Solarea Bio, a biotech company based in Cambridge, MA that is developing microbial-based solutions to aid human health, announced it has signed a technology licensing agreement with global nutrition leader ADM (NYSE: ADM). Solarea Bio has developed […]
Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of a $37.25 million Series C financing. OneVentures, a venture capital firm headquartered in Sydney, […]
Nascent, Complex, and Evolving Market The microbial population in the human body the human microbiome numbers in the trillions,(1) and genes within these microbes are often referred to as the “second genome”(2). Most commensal, symbiotic, […]